Biogen

+$1.98 (+0.97%) Today

$0.00 (0.00%) As of 12:00 AM UTC after-hours

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Biogen and other ETFs, options, and stocks.

About BIIB

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis, SPINRAZA for the treatment of spinal muscular atrophy, and FUMADERM for the treatment of severe plaque psoriasis.

CEO

Michel Vounatsos

Employees

9,610

Headquarters

Cambridge, Massachusetts

Founded

1978

BIIB Key Statistics

Market cap

Price-Earnings ratio

21.13

Dividend yield

—

Average volume

927.80K

High today

$207.36

Low today

$203.13

Open price

$205.26

Volume

1.01M

52 Week high

$468.55

52 Week low

$187.16

BIIB News

Simply Wall StMay 24

How Much Of Biogen Inc. Do Institutions Own? - Simply Wall St

If you want to know who really controls Biogen Inc. ( ), then you'll have to look at the makeup of its share registry. Institutions will often hold stock in big

Barron'sMay 24

Who Will Lead Biogen? Some Likely CEO Picks From Analyst. - Barron's

Biogen set off a high-stakes guessing game early this month when it announced that its CEO Michel Vounatsos would leave, after the company effectively threw in

Barron'sMay 24

Who Will Lead Biogen? This Analyst Offers Some Likely Picks.

Text size Biogen set off a high-stakes guessing game early this month when it announced that its CEO Michel Vounatsos would leave, after the company effectivel

Analyst ratings

Buy

47.1%

Hold

50%

Sell

2.9%

BIIB Earnings

$0.00

$2.95

$5.89

$8.84

Q3 FY20

Q4 FY20

Q1 FY21

Q2 FY21

Q3 FY21

Q4 FY21

Q1 FY22

Q2 FY22

Estimated

— per share

Actual

Expected Jul 28, Pre-Market

More BIIB News

BenzingaMay 23

Researchers Investigate New Treatment Pathways For Alzheimer's After Commercial Failure Of Biogen's Aduhelm

The commercial failure of Biogen Inc's BIIB drug Aduhelm has put a new focus on the research into the causes of Alzheimer's disease. Aduhelm was expected as a